IC
PNT

Ikarian Capital’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Ikarian Capital’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,784
Closed -$261K – 176
2023
Q2 		$261K Sell
28,784
-110,781
-79% -$977K 0.04% 108
2023
Q1 		$1.01M Hold
139,565
– – 0.23% 77
2022
Q4 		$1.02M Sell
139,565
-310,841
-69% -$2.31M 0.25% 50
2022
Q3 		$3.48M Buy
+450,406
New +$3.82M 0.69% 45

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's PNT Position: Q3 2023 in Review

Ikarian Capital sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 28,784 shares — an estimated $261K sold.

Ikarian Capital first reported a position in PNT in Q3 2022 and held it in 4 quarters. The position peaked at $3.48M in Q3 2022. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Ikarian Capital reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 28,784 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $261K.
  • Ikarian Capital first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Ikarian Capital's POINT Biopharma Global Inc. Common Stock position peaked at $3.48M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.